Alerts
PDF
Other content recommended for you
- Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer
- Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
- Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
- Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas
- Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma
- CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency
- Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors
- Acceptability of donor funding for clinical trials in the UK: a qualitative empirical ethics study using focus groups to elicit the views of research patient public involvement group members, research ethics committee chairs and clinical researchers
- Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma
- Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy